{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T22:52:16Z","timestamp":1790031136330,"version":"4.0.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"6963","license":[{"start":{"date-parts":[[2003,10,26]],"date-time":"2003-10-26T00:00:00Z","timestamp":1067126400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2003,10,26]],"date-time":"2003-10-26T00:00:00Z","timestamp":1067126400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nature"],"published-print":{"date-parts":[[2003,11,13]]},"DOI":"10.1038\/nature02099","type":"journal-article","created":{"date-parts":[[2003,10,26]],"date-time":"2003-10-26T12:57:30Z","timestamp":1067173050000},"page":"186-189","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":766,"title":["An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus"],"prefix":"10.1038","volume":"426","author":[{"given":"Daniel","family":"Lamarre","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul C.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murray","family":"Bailey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Beaulieu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordon","family":"Bolger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Bonneau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"B\u00f6s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dale R.","family":"Cameron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mireille","family":"Cartier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael G.","family":"Cordingley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Marie","family":"Faucher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Goudreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen H.","family":"Kawai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Kukolj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisette","family":"Lagac\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven R.","family":"LaPlante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Narjes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc-Andr\u00e9","family":"Poupart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Rancourt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roel E.","family":"Sentjens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"St George","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Simoneau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard","family":"Steinmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"Thibeault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youla S.","family":"Tsantrizos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven M.","family":"Weldon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chan-Loi","family":"Yong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Montse","family":"Llin\u00e0s-Brunet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2003,10,26]]},"reference":[{"key":"BFnature02099_CR1","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1126\/science.2523562","volume":"244","author":"QL Choo","year":"1989","unstructured":"Choo, Q. L. et al. Isolation of a cDNA clone derived from a blood-borne non-A non-B viral hepatitis genome. Science 244, 359\u2013362 (1989)","journal-title":"Science"},{"key":"BFnature02099_CR2","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1126\/science.2496467","volume":"244","author":"G Kuo","year":"1989","unstructured":"Kuo, G. et al. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science 244, 362\u2013364 (1989)","journal-title":"Science"},{"key":"BFnature02099_CR3","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/S0140-6736(97)07361-3","volume":"351","author":"AM Di Bisceglie","year":"1998","unstructured":"Di Bisceglie, A. M. Hepatitis C. Lancet 351, 351\u2013355 (1998)","journal-title":"Lancet"},{"key":"BFnature02099_CR4","doi-asserted-by":"crossref","first-page":"S135","DOI":"10.1002\/hep.1840360718","volume":"36","author":"G Chander","year":"2002","unstructured":"Chander, G. et al. Treatment of chronic hepatitis C: a systematic review. Hepatology 36, S135 (2002)","journal-title":"Hepatology"},{"key":"BFnature02099_CR5","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1038\/nrd937","volume":"1","author":"S-L Tan","year":"2002","unstructured":"Tan, S.-L., Pause, A., Shi, Y. & Sonenberg, N. Hepatitis C therapeutics: current status and emerging strategies. Nature Rev. Drug Discov. 1, 867\u2013881 (2002)","journal-title":"Nature Rev. Drug Discov."},{"key":"BFnature02099_CR6","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1053\/jhep.2002.30531","volume":"35","author":"AM Di Bisceglie","year":"2002","unstructured":"Di Bisceglie, A. M., McHutchison, J. & Rice, C. M. New therapeutic strategies for hepatitis C. Hepatology 35, 224\u2013231 (2002)","journal-title":"Hepatology"},{"key":"BFnature02099_CR7","first-page":"55","volume":"242","author":"KE Reed","year":"2000","unstructured":"Reed, K. E. & Rice, C. M. Overview of hepatitis C virus genome structure, polyprotein processing, and protein properties. Curr. Top. Microbiol. Immunol. 242, 55\u201384 (2000)","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"BFnature02099_CR8","doi-asserted-by":"publisher","first-page":"2046","DOI":"10.1128\/JVI.74.4.2046-2051.2000","volume":"74","author":"AA Kolykhalov","year":"2000","unstructured":"Kolykhalov, A. A., Mihalik, K., Feinstone, S. M. & Rice, C. M. Hepatitis C virus-encoded enzymatic activities and conserved RNA elements in the 3\u2032 nontranslated region are essential for virus replication in vivo. J. Virol. 74, 2046\u20132051 (2000)","journal-title":"J. Virol."},{"key":"BFnature02099_CR9","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1126\/science.285.5424.110","volume":"285","author":"V Lohmann","year":"1999","unstructured":"Lohmann, V. et al. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 285, 103\u2013107 (1999)","journal-title":"Science"},{"key":"BFnature02099_CR10","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1038\/90968","volume":"7","author":"DF Mercer","year":"2001","unstructured":"Mercer, D. F. et al. Hepatitis C virus replication in mice with chimeric human livers. Nature Med. 7, 927\u2013933 (2001)","journal-title":"Nature Med."},{"key":"BFnature02099_CR11","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/S0006-291X(67)80055-X","volume":"27","author":"I Schechter","year":"1967","unstructured":"Schechter, I. & Berger, A. Protease subsite nomenclature. Biochem. Biophys. Res. Commun. 27, 157\u2013162 (1967)","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"BFnature02099_CR12","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1016\/S0960-894X(98)00299-6","volume":"8","author":"M Llin\u00e0s-Brunet","year":"1998","unstructured":"Llin\u00e0s-Brunet, M. et al. Peptide-based inhibitors of the hepatitis C virus serine protease. Bioorg. Med. Chem. Lett. 8, 1713\u20131718 (1998)","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"BFnature02099_CR13","doi-asserted-by":"publisher","first-page":"8899","DOI":"10.1021\/bi980313v","volume":"37","author":"C Steink\u00fchler","year":"1998","unstructured":"Steink\u00fchler, C. et al. Product inhibition of the hepatitis C virus NS3 protease. Biochemistry 37, 8899\u20138905 (1998)","journal-title":"Biochemistry"},{"key":"BFnature02099_CR14","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.1016\/S0960-894X(98)00480-6","volume":"8","author":"M Llin\u00e0s-Brunet","year":"1998","unstructured":"Llin\u00e0s-Brunet, M. et al. Studies on the C-terminal of hexapeptide inhibitors of the hepatitis C virus serine protease. Bioorg. Med. Chem. Lett. 8, 2719\u20132724 (1998)","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"BFnature02099_CR15","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1016\/S0960-894X(00)00465-0","volume":"10","author":"M Llin\u00e0s-Brunet","year":"2000","unstructured":"Llin\u00e0s-Brunet, M. et al. Highly potent and selective peptide-based inhibitors of the hepatitis C virus serine protease: towards smaller inhibitors. Bioorg. Med. Chem. Lett. 10, 2267\u20132270 (2000)","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"BFnature02099_CR16","doi-asserted-by":"publisher","first-page":"4743","DOI":"10.1021\/jo010164d","volume":"66","author":"M-A Poupart","year":"2001","unstructured":"Poupart, M.-A. et al. Solid-phase synthesis of peptidomimetic inhibitors for the hepatitis C virus NS3 protease. J. Org. Chem. 66, 4743\u20134751 (2001)","journal-title":"J. Org. Chem."},{"key":"BFnature02099_CR17","unstructured":"Goudreau, N. et al. NMR structural characterization of peptide inhibitors bound to the HCV NS3 protease: design of a new P2 substituent. J. Med. Chem. (submitted)"},{"key":"BFnature02099_CR18","doi-asserted-by":"publisher","first-page":"20374","DOI":"10.1074\/jbc.M210785200","volume":"278","author":"A Pause","year":"2003","unstructured":"Pause, A. et al. An NS3 serine protease inhibitor abrogates replication of subgenomic hepatitis C virus RNA. J. Biol. Chem. 278, 20374\u201320380 (2003)","journal-title":"J. Biol. Chem."},{"key":"BFnature02099_CR19","doi-asserted-by":"publisher","first-page":"18618","DOI":"10.1074\/jbc.274.26.18618","volume":"274","author":"SR LaPlante","year":"1999","unstructured":"LaPlante, S. R. et al. Solution structure of substrate-based ligands when bound to hepatitis C virus NS3 protease domain. J. Biol. Chem. 274, 18618\u201318624 (1999)","journal-title":"J. Biol. Chem."},{"key":"BFnature02099_CR20","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1016\/S0960-894X(00)00466-2","volume":"10","author":"SR LaPlante","year":"2000","unstructured":"LaPlante, S. R. et al. NMR line-broadening and transferred NOESY as a medicinal chemistry tool for studying inhibitors of the hepatitis C virus NS3 protease domain. Bioorg. Med. Chem. Lett. 10, 2271\u20132274 (2000)","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"BFnature02099_CR21","unstructured":"Boehringer Ingelheim (Canada) Ltd. Hepatitis C inhibitor tripeptides. US patent 6,323,180 B1 (2001)."},{"key":"BFnature02099_CR22","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1002\/anie.200390347","volume":"42","author":"Y Tsantrizos","year":"2003","unstructured":"Tsantrizos, Y. et al. Macrocyclic inhibitors of the NS3 protease as potential therapeutic agents of hepatitis C virus infection. Angew. Chem. Int. Edn Engl. 42, 1356\u20131360 (2003)","journal-title":"Angew. Chem. Int. Edn Engl."},{"key":"BFnature02099_CR23","first-page":"800","volume":"36(4)","author":"H Narjes","year":"2002","unstructured":"Narjes, H., Yong, C. L., Stahle, H. & Steinmann, G. Tolerability and pharmacokinetics of BILN 2061: a novel serine protease HCV inhibitor after oral single doses of 5\u2009mg to 2,400\u2009mg in healthy male subjects. Hepatology 36(4), Abst. 800 (2002)","journal-title":"Hepatology"},{"key":"BFnature02099_CR24","first-page":"866","volume":"36","author":"H Hinrichsen","year":"2002","unstructured":"Hinrichsen, H. et al. First report on the antiviral efficacy of BILN 2061, a novel oral serine protease inhibitor, in patients with chronic hepatitis C genotype 1. Hepatology 36, 297A, Abst. 866 (2002)","journal-title":"Hepatology"},{"key":"BFnature02099_CR25","first-page":"563","volume":"36","author":"Y Benhamou","year":"2002","unstructured":"Benhamou, Y. et al. Safety, tolerability and antiviral effect of BILN 2061, a novel HCV serine protease inhibitor, after oral treatment over 2 days in patients with chronic hepatitis C, genotype 1, with advanced liver fibrosis. Hepatology 36, 304A, Abst. 563 (2002)","journal-title":"Hepatology"},{"key":"BFnature02099_CR26","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1126\/science.282.5386.103","volume":"282","author":"AU Neumann","year":"1998","unstructured":"Neumann, A. U. et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 282, 103\u2013107 (1998)","journal-title":"Science"},{"key":"BFnature02099_CR27","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1086\/315661","volume":"182","author":"AU Neumann","year":"2000","unstructured":"Neumann, A. U. et al. Differences in viral dynamics between genotypes 1 and 2 of hepatitis C virus. J. Infect. Dis. 182, 28\u201335 (2000)","journal-title":"J. Infect. Dis."},{"key":"BFnature02099_CR28","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1053\/gast.2001.24006","volume":"120","author":"S Zeuzem","year":"2001","unstructured":"Zeuzem, S. et al. Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon alpha 2a. Gastroenterology 120, 1438\u20131447 (2001)","journal-title":"Gastroenterology"},{"key":"BFnature02099_CR29","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1126\/science.1082604","volume":"300","author":"E Foy","year":"2003","unstructured":"Foy, E. et al. Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease. Science 300, 1145\u20131148 (2003)","journal-title":"Science"},{"key":"BFnature02099_CR30","unstructured":"Boehringer Ingelheim (Canada) Ltd. Macrocyclic peptides active against the Hepatitis C virus. US patent 6,608,027 B1 (2003)."}],"updated-by":[{"DOI":"10.1038\/nature02183","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2003,11,20]],"date-time":"2003-11-20T00:00:00Z","timestamp":1069286400000}}],"container-title":["Nature"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nature02099.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nature02099","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nature02099.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,14]],"date-time":"2024-12-14T00:16:52Z","timestamp":1734135412000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nature02099"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,10,26]]},"references-count":30,"journal-issue":{"issue":"6963","published-print":{"date-parts":[[2003,11,13]]}},"alternative-id":["BFnature02099"],"URL":"https:\/\/doi.org\/10.1038\/nature02099","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.1005559.200425","asserted-by":"object"}]},"ISSN":["0028-0836","1476-4687"],"issn-type":[{"value":"0028-0836","type":"print"},{"value":"1476-4687","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,10,26]]},"assertion":[{"value":"25 August 2003","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2003","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2003","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have amended their Competing interests statement: it previously read 'The authors declare that they have no competing financial interests.' it should read \u2018The authors declare competing financial interests: R.E.S. was the clinical investigator and received an honorarium from Boehringer Ingelheim. All the other authors are or were employees of Boehringer Ingelheim.\u2019 A Corrigendum will soon be published.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}